Scarica l'app Stockscreener
31.27
1.83%
0.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$30.70
Aprire:
$31.35
Volume 24 ore:
1.64M
Relative Volume:
0.45
Capitalizzazione di mercato:
$3.51B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-33.62
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
+2.83%
1M Prestazione:
+15.95%
6M Prestazione:
-3.99%
1 anno Prestazione:
-45.16%
Intervallo 1D:
$30.67
$31.94
Intervallo di 1 settimana:
$29.76
$32.10
Portata 52W:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.29 | 3.39B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.56 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.40 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.03 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.60 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.17 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Nasdaq
VKTX August 29th Options Begin Trading - Nasdaq
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies - Seeking Alpha
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results - Insider Monkey
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Yahoo Finance
This Insider Has Just Sold Shares In Viking Therapeutics - simplywall.st
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - MSN
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity - The Motley Fool
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts (NASDAQ:VKTX) - Seeking Alpha
August 22nd Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
Viking Therapeutics, Inc.(NasdaqCM: VKTX) added to Russell Midcap Value Index - MarketScreener
Viking Therapeutics (VKTX): A High-Risk, High-Reward Biotech Play with Institutional Backing - AInvest
Viking Therapeutics (VKTX): Riding Clinical Catalysts in a Post-Danuglipron World - AInvest
Why This Weight Loss Drug Company's Stock Surged Today - AOL.com
Viking Therapeutics stock maintains buy rating as phase 3 trials begin - Investing.com
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 - Yahoo Finance
Viking's New Obesity Drug Enters Final Testing Phase: 14.7% Weight Loss in Earlier Trial Sparks Interest - Stock Titan
Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)? - MSN
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - Yahoo Finance
(VKTX) Proactive Strategies - news.stocktradersdaily.com
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - MSN
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely - Yahoo Finance
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Investors Are Gobbling Up Shares of These 10 Firms - Insider Monkey
Viking Therapeutics (VKTX) to Participate in B. Riley's Montreal Meeting | VKTX Stock News - GuruFocus
Jim Cramer Nailed These 11 Stock Predictions - Insider Monkey
1 Stock Down 34% This Year to Buy and Hold - AOL.com
Transcript : Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - marketscreener.com
July 25th Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
(VKTX) Investment Analysis - news.stocktradersdaily.com
Viking Therapeutics at Jefferies Conference: Promising Weight Loss Drug - Investing.com
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Could Viking Therapeutics Become the Next Eli Lilly? - The Globe and Mail
3 Best Growth Stocks to Buy in June - The Motley Fool
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM (NVDA:NASDAQ) - Seeking Alpha
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade) - Seeking Alpha
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences | VKTX Stock News - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences – Company Announcement - Financial Times
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
3.40%
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):